Article
Ascidian Therapeutics rises from ATP's ocean floor with $50M and Dyne's former CEO
Rating:
0.0
Views:
58
Likes:
1
Library:
1
Inspired by ocean “sea squirts,” Ascidian Therapeutics is floating to the surface with $50 million in series A treasure to fund its ambitions to rewrite RNA for therapeutic benefit. | Ascidian Therapeutics is launching up from the ocean floor with $50 million in series A funds. The company's primary focus is the continued development of its lead asset targeting ABCA4 gene mutations.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value